Endometrium Kanseri, Sirkadiyen Ritim ve Kronokemoterapi
Özet
Endometrium kanseri, rahim iç tabakasından kaynaklanan ve sıklıkla menopoz sonrası görülen bir kanser türüdür. Tedavisinde cerrahi, kemoterapi gibi yöntemler kullanılırken, son yıllarda sirkadiyen ritmin önemi giderek artmaktadır. Sirkadiyen ritim, vücudun 24 saatlik döngüsünü düzenleyen, hücre bölünmesi, DNA onarımı gibi temel süreçleri etkileyen karmaşık bir sistemdir. Bu ritim, hipotalamustaki suprakiyazmatik nükleus (SKN) tarafından yönetilir ve CLOCK, BMAL1, PER, CRY gibi genler tarafından kontrol edilir. Bu genlerin ve proteinlerin etkileşimi, hücre içinde ritmik bir salınım oluşturarak diğer genlerin ve hücresel işlevlerin zamanlamasını belirler.
Kronokemoterapi, kemoterapi ilaçlarının sirkadiyen ritme uygun zamanlarda verilerek etkinliğin artırılması ve yan etkilerin azaltılması yaklaşımıdır. Ancak, bu konuda çelişkili sonuçlar vardır ve daha fazla çalışmaya ihtiyaç duyulmaktadır. Sirkadiyen ritmi düzenleyen faktörlerin (örn., ışık, uyku, melatonin) kanser tedavisindeki rolü araştırılmaktadır. Sirkadiyen ritim bozukluklarının düzeltilmesi, tedavi etkinliğini artırmanın yanı sıra hastaların yaşam kalitesini de iyileştirebilir. Gelecekte, kişiye özel tedavi yaklaşımlarında sirkadiyen ritmin daha fazla dikkate alınması ve bu biyolojik saate özgü tedavi stratejilerinin geliştirilmesi hedeflenmektedir. Bu, hem tedavi başarısını artırabilir hem de yan etkileri en aza indirebilir.
Endometrial cancer is a type of cancer that originates from the inner layer of the uterus and is often detected after menopause. While treatments such as surgery and chemotherapy are available, the significance of circadian rhythm has gained attention in recent years. The circadian rhythm is a complex system that regulates the body's 24-hour cycle and influences essential processes like cell division and DNA repair. This rhythm is controlled by the suprachiasmatic nucleus (SCN) in the hypothalamus and is impacted by genes such as CLOCK, BMAL1, PER, and CRY. The interaction among these genes and proteins generates a rhythmic oscillation within the cell, determining the timing of various genes and cellular functions.
Chronochemotherapy aims to enhance efficacy and reduce side effects by administering chemotherapy drugs at times that align with the circadian rhythm. However, conflicting results remain, indicating that further studies are necessary. The effects of factors that influence circadian rhythms, such as light, sleep, and melatonin, on cancer treatment are currently under investigation. Correcting disturbances in circadian rhythms may not only enhance treatment efficacy but also enhance patients' quality of life. In the future, more effectively integrating circadian rhythms into personalized treatment strategies and developing approaches tailored to this biological clock may increase treatment success and reduce side effects.
Referanslar
Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399(10333):1412-1428. doi:10.1016/S0140-6736(22)00323-3
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109(3):655-662. doi:10.1097/01.AOG.0000255980.88205.15
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2017 Jul 1;28(suppl_4):iv167-iv168. doi: 10.1093/annonc/mdx258]. Ann Oncol. 2016;27(1):16-41. doi:10.1093/annonc/mdv484
Li HX. The role of circadian clock genes in tumors. Onco Targets Ther. 2019;12:3645-3660. Published 2019 May 13. doi:10.2147/OTT.S203144
Korenčič A, Košir R, Bordyugov G, et al. Timing of circadian genes in mammalian tissues. Sci Rep. 2014;4:5782. Published 2014 Jul 22. doi:10.1038/srep05782
Rashed N, Liu W, Zhou X, et al. The role of circadian gene CLOCK in cancer. Biochim Biophys Acta Mol Cell Res. 2024;1871(7):119782. doi:10.1016/j.bbamcr.2024.119782
Tokunaga H, Takebayashi Y, Utsunomiya H, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87(10):1060-1070. doi:10.1080/00016340802348286
Li DD, Zhou T, Gao J, et al. Circadian rhythms and breast cancer: from molecular level to therapeutic advancements. J Cancer Res Clin Oncol. 2024;150(9):419. Published 2024 Sep 12. doi:10.1007/s00432-024-05917-w
Sancar A, Lindsey-Boltz LA, Gaddameedhi S, et al. Circadian clock, cancer, and chemotherapy. Biochemistry. 2015;54(2):110-123. doi:10.1021/bi5007354
Dana PM, Sadoughi F, Mobini M, et al. Molecular and Biological Functions of Melatonin in Endometrial Cancer. Curr Drug Targets. 2020;21(5):519-526. doi:10.2174/1389450120666190927123746
Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res. 2007;67(21):10618-10622. doi:10.1158/0008-5472.CAN-07-2485
Medgyesi DN, Trabert B, Fisher JA, et al. Outdoor light at night and risk of endometrial cancer in the NIH-AARP diet and health study. Cancer Causes Control. 2023;34(2):181-187. doi:10.1007/s10552-022-01632-4
Wang Z, Wang H, Wang Z, et al. Associated analysis of PER1/TUBB2B with endometrial cancer development caused by circadian rhythm disorders. Med Oncol. 2020;37(10):90. Published 2020 Sep 14. doi:10.1007/s12032-020-01415-4
Costas L, Frias-Gomez J, Benavente Moreno Y, et al. Night work, chronotype and risk of endometrial cancer in the Screenwide case-control study. Occup Environ Med. Published online February 24, 2022. doi:10.1136/oemed-2021-108080
Shih HC, Choo KB, Chang TJ, et al. Disturbance of circadian gene expression in endometrial cancer: detection by real-time quantitative RT-PCR. Oncol Rep. 2005;14(6):1533-1538.
Yeh KT, Yang MY, Liu TC, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol. 2005;206(1):111-120. doi:10.1002/path.1756
Hermyt E, Zmarzly N, Kruszniewska-Rajs C, et al. Expression pattern of circadian rhythm-related genes and its potential relationship with miRNAs activity in endometrial cancer. Ginekol Pol. 2023;94(1):33-40. doi:10.5603/GP.a2022.0063
Zheng X, Lv X, Zhu L, et al. The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma. Cancer Manag Res. 2021;13:9329-9343. Published 2021 Dec 22. doi:10.2147/CMAR.S343097
Shih MC, Yeh KT, Tang KP, et al. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog. 2006;45(10):732-740. doi:10.1002/mc.20198
Ver Hoeve ES, Rumble ME, Gorzelitz JS, et al. Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors. Gynecol Oncol. 2024;191:265-274. doi:10.1016/j.ygyno.2024.10.024
Bestvina CM, Fleming GF. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist. 2016;21(10):1250-1259. doi:10.1634/theoncologist.2016-0062
Yang Y, Adebali O, Wu G, et al. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues. Proc Natl Acad Sci U S A. 2018;115(21):E4777-E4785. doi:10.1073/pnas.1804493115
Kobayashi, M., Wood, P. A., & Hrushesky, W. J. (2002). Circadian chemotherapy for gynecological and genitourinary cancers. Chronobiology International, 19(1), 237–251. doi:10.1081/cbi-120002600
Barrett RJ, Blessing JA, Homesley HD, et al. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol. 1993;16(6):494-496. doi:10.1097/00000421-199312000-00007
Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21(20):3808-3813. doi:10.1200/JCO.2003.10.083
